Although PSMA-targeted imaging has been very effective in detection of PSMA expressing tumors, prostate cancers with neuroendocrine differentiation do not express PSMA due to FOLH1 gene suppression and thus, making this imaging technique ineffective [9]. This evidence concerns the gene FOLH1 and prostate cancer.